Skip to main content

Development of early non-invasive biomarkers and means for the diagnosis and progression monitoring of pre-eclampsia and tailoring putative therapies

Objective

Preeclampsia (PET), de-novo hypertension & proteinuria after mid gestation, affects 5-7% of all pregnancies. Cases may develop life threatening haemolysis-elevated liver enzymes-low platelets (HELLP) or renal failure, cerebral haemorrhages & eclampsia, IUGR, placental abruption & death. We will identify markers for PET risk prediction in the 1st trimester to allow longer time for tailoring putative medications to prevent PET; and assess & characterize plausible links between marker shortage/access, PET & putative medications in in vitro systems to fit putative medications to pre-defined disease-risk women. Candidates for 1st trimester risk prediction of PET (cell free DNA & RNA, serum PP13, ADAM12, PAPP-A) will be verified with new ones using genomics & proteomics. Our blood, urine & fixed placenta tissue banks of pregnant women enable comparative analysis to build integrative, non-invasive Marker Effectiveness Profiles (MEPs) to PET subtypes (early/late onset, mild/severe, HELLP & IUGR). Disease progressions will be detected by continuous marker monitoring. Expertise in trophoblast in-vitro systems (placenta explants & cell lines) and quantitative real time PCR, genomics & proteomics, immunohistochemistry & confocal microscopy will verify markers' roles and identify links to curing effects of putative medications. We will model 'Putative Medication Benefit Arrays' (PMBAs) for PET subtypes matched to MEPs. We will develop non-invasive diagnostic kits for 1st trimester PET prediction based on markers, antibodies, oligos & siRNA and others coupled to the power of Doppler ultrasound. Nested case-control clinical studies will test effectiveness of combined diagnosis & drug tailoring. Trans-European prospective clinical study, combining early diagnosis & randomising putative medication will verify findings. R&D results will be used to train physicians & patients, to implement new prenatal care practice and eradicate preeclampsia.'

Call for proposal

FP6-2005-LIFESCIHEALTH-7
See other projects for this call

Coordinator

DIAGNOSTIC TECHNOLOGIES LTD.
Address
2 Ha'carmel Street
Yoqne'am
Israel

See on map

Participants (10)

GLOBAL RESEARCH AND FINANCING
Israel
Address
15, Balfour Street
Tel-aviv

See on map

BARKING, HAVERING & REDBRIDGE HOSPITALS NHS TRUST
United Kingdom
Address
Harold Wood Hospital, Gubbins Lane
Romford, Essex

See on map

MEDICAL UNIVERSITY OF GRAZ
Austria
Address
Universitaetsplatz 3
Graz

See on map

SEMMELWEIS EGYETEM
Hungary
Address
Ülloi U. 26
Budapest

See on map

WALLAC OY
Finland
Address
Mustionkatu 6
Turku

See on map

FOETAL MEDICINE FOUNDATION
United Kingdom
Address
137 Harley Street
London

See on map

INNOMEDICA OY LTD.
Finland
Address
Tykistökatu 6 B
Turku

See on map

IMUNOSTAR - INVESTIGAÇÃO E COMERCIALIZAÇÃO DE PRODUTOS DE BIODIAGÓSTICO S.A.
Portugal
Address
Rua Do Campo Alegre, 823
Porto

See on map

Links
UNIVERSITÀ DEGLI STUDI DI MILANO
Italy
Address
Via Festa Del Perdono 7
Milano

See on map

UNIVERSITÄT BASEL
Switzerland
Address
Petersplatz 1
Basel

See on map